Emergent BioSolutions Inc. (EBS)
NYSE: EBS · Real-Time Price · USD
4.830
-0.340 (-6.58%)
At close: Apr 3, 2025, 4:00 PM
4.910
+0.080 (1.66%)
After-hours: Apr 3, 2025, 8:00 PM EDT

Company Description

Emergent BioSolutions Inc., a life sciences company, provides preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats in the United States.

The company offers NARCAN Nasal Spray for the emergency treatment of known or suspected opioid overdose; Vaxchora vaccine for the prevention of cholera; Vivotif vaccine for oral administration for the prevention of typhoid fever; Anthrasil for the treatment of inhalational anthrax; BioThrax, an anthrax vaccine; CYFENDUS for post-exposure prophylaxis of disease following suspected or confirmed exposure to Bacillus anthracis; and Raxibacumab injection for the treatment and prophylaxis of inhalational anthrax.

It provides ACAM2000, a smallpox vaccine; CNJ-016 to address complications from smallpox vaccination; TEMBEXA for the treatment of smallpox disease caused by variola virus in adult and pediatric patients; Botulism Antitoxin Heptavalent for the treatment of symptomatic botulism; Ebanga for the treatment of Ebola; Trobigard, an atropine sulfate obidoxime chloride auto-injector.

In addition, the company is developing EBS-LASV to prevent Lassa fever; EBS-MARV to prevent Marburg virus disease; EBS-SUDV to prevent Sudan virus disease; Pan-Ebola mAbs for the treatment of ebola virus; and WEVEE-VLP for equine encephalitis virus infections.

Further, it provides contract development and manufacturing services comprising drug substance and product manufacturing, and packaging, as well as technology transfer, process, and analytical development services.

The company was incorporated in 1998 and is headquartered in Gaithersburg, Maryland.

Emergent BioSolutions Inc.
Emergent BioSolutions logo
Country United States
Founded 1998
IPO Date Nov 15, 2006
Industry Drug Manufacturers - Specialty & Generic
Sector Healthcare
Employees 900
CEO Joseph Papa

Contact Details

Address:
300 Professional Drive
Gaithersburg, Maryland 20879
United States
Phone 240 631 3200
Website emergentbiosolutions.com

Stock Details

Ticker Symbol EBS
Exchange NYSE
Stock Type Common Stock
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001367644
CUSIP Number 29089Q105
ISIN Number US29089Q1058
Employer ID 14-1902018
SIC Code 2834

Key Executives

Name Position
Joseph C. Papa Jr. Chief Executive Officer, President and Director
Richard S. Lindahl M.B.A. Executive Vice President, Chief Financial Officer and Treasurer
Coleen Glessner Chief Quality and Compliance Officer
Paul A. Williams Senior Vice President of Products Business
William Hartzel Senior Vice President of Manufacturing and Bioservices
Jessica Perl Senior Vice President, Corporate Secretary and General Counsel
Michelle Pepin Senior Vice President and Chief Human Resource Officer
Stephanie Duatschek Senior Vice President and Chief Strategy and Transformation Officer
Simon C. Lowry M.D. Chief Medical Officer and Head of Research and Development

Latest SEC Filings

Date Type Title
Mar 31, 2025 8-K Current Report
Mar 24, 2025 EFFECT Notice of Effectiveness
Mar 24, 2025 424B3 Prospectus
Mar 24, 2025 8-K Current Report
Mar 21, 2025 DEF 14A Other definitive proxy statements
Mar 21, 2025 DEFA14A Additional definitive proxy soliciting materials and Rule 14(a)(12) material
Mar 21, 2025 ARS Filing
Mar 12, 2025 144 Filing
Mar 12, 2025 144 Filing
Mar 10, 2025 8-K Current Report